These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25618630)

  • 1. Targeted programmed cell death in lung cancer treatment.
    Zimmerman MP; Mehr SR
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E3. PubMed ID: 25618630
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab provides favorable results in patients with advanced melanoma.
    Dangi-Garimella S
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E11. PubMed ID: 25618626
    [No Abstract]   [Full Text] [Related]  

  • 3. PD-1-targeted immunotherapy: recent clinical findings.
    Brahmer JR
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
    [No Abstract]   [Full Text] [Related]  

  • 4. First-Line Immune Therapy-Implications for Pathologists.
    Miller RA; Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2016 Aug; 140(8):739-40. PubMed ID: 27472228
    [No Abstract]   [Full Text] [Related]  

  • 5. [Is it possible to treat bronchial carcinoma without chemotherapy?].
    Pujol JL
    Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S23-10S26. PubMed ID: 17127957
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
    Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
    [No Abstract]   [Full Text] [Related]  

  • 9. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More Benefits for Checkpoint Inhibitors in NSCLC.
    Cancer Discov; 2015 Dec; 5(12):OF2. PubMed ID: 26511141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Association of Cancer Research Showcases Immunotherapy Advances.
    Brower V
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
    [No Abstract]   [Full Text] [Related]  

  • 12. [Not Available].
    Moro-Sibilot D; Ferrer L; Levra MG; Toffart AC
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S12-5. PubMed ID: 27494968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy drug improves survival of patients with squamous non-small cell lung cancer.
    Printz C
    Cancer; 2015 Oct; 121(20):3562-3. PubMed ID: 26431439
    [No Abstract]   [Full Text] [Related]  

  • 14. Checkpoint inhibitor shows promise in smokers.
    Cancer Discov; 2013 Dec; 3(12):OF8. PubMed ID: 24327717
    [No Abstract]   [Full Text] [Related]  

  • 15. Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.
    Ulmeanu R; Antohe I; Anisie E; Antoniu S
    Expert Rev Anticancer Ther; 2016; 16(2):165-7. PubMed ID: 26634873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
    Bearz A; Serraino D; Fratino L; Berretta M; Tirelli U
    Cancer; 2007 Dec; 110(11):2593-4; author reply 2594. PubMed ID: 17960771
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeted therapies in non-small-cell lung cancer: a paradigm in evolution.
    Sangha R; Lara PN; Mack P; Gandara DR
    Clin Lung Cancer; 2008; 9 Suppl 3():S90-1. PubMed ID: 19419929
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
    Pirker R
    Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
    Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
    J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer.
    Helissey C; Champiat S; Soria JC
    Curr Opin Oncol; 2015 Mar; 27(2):108-17. PubMed ID: 25602683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.